Anti-Transcriptional Intermediary Factor 1 Gamma Antibody-Positive Dermatomyositis Concomitant with Diffuse Large B-Cell Lymphoma: Case Report and Literature Review
Case Reports in Oncology · 27.08.2026 · 19 (1) · 1451-1458
DOI: 10.1159/cro/abzag037 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 27.08.2026. Verfasst von Hajime Yasuda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Anti-transcriptional intermediary factor 1 gamma antibody-positive dermatomyositis (anti-TIF1-γ-DM) is a paraneoplastic syndrome occurring in various neoplasms, but reports elaborating on anti-TIF1-γ-DM patients accompanied by lymphoma are scarce. We report 2 patients with diffuse large B-cell lymphoma (DLBCL) complicated by anti-TIF1-γ-DM and carried out TIF1-γ immunohistochemistry on tissue sections of DLBCL and skin of anti-TIF1-γ-DM patients and controls. Genetic analysis of exons 2 and 10 of TRIM33, the gene coding TIF1-γ, was also carried out in DLBCL and skin samples of anti-TIF1-γ-DM patients and controls to look for recurrent mutations. Case Presentation: Case 1 was a 65-year-old male and case 2 was a 52-year-old male, and both patients presented with DLBCL complicated by anti-TIF1-γ-DM. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy led to remissions of both anti-TIF1-γ-DM and DLBCL in both cases. Immunohistochemistry showed strong TIF1-γ expression in DLBCL and skin samples from both patients with anti-TIF1-γ-DM and controls. Mutations in exons 2 and 10 of TRIM33 have been previously reported in DLBCL cells of an anti-TIF1-γ-DM patient, but analysis of the same exons revealed no recurrent mutations in our cases.
Conclusion
Anti-TIF1-γ-DM very often presents with a concomitant neoplasm, and a systemic evaluation for malignancy including lymphoma is mandatory. The etiology of anti-TIF1-γ-DM in patients with lymphoma remains unknown, and the underlying mechanisms have yet to be elucidated.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Orthopedic Surgery, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Laboratory of Morphology and Image Analysis, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Cell Therapy and Transfusion Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
ORCID-Profile: Yoshiyuki Abe
Zitieren
APA
Yasuda, H., Ishii, M., Maruyama, K., Sano, Y., Kojima, Y., Abe, Y., Kinoshita, S., Hamano, Y., Ando, J., & Ando, M. (2026). Anti-Transcriptional Intermediary Factor 1 Gamma Antibody-Positive Dermatomyositis Concomitant with Diffuse Large B-Cell Lymphoma: Case Report and Literature Review. Case Reports in Oncology, 19(1), 1451-1458. https://doi.org/10.1159/cro/abzag037
Vancouver
Yasuda H, Ishii M, Maruyama K, Sano Y, Kojima Y, Abe Y, et al. Anti-Transcriptional Intermediary Factor 1 Gamma Antibody-Positive Dermatomyositis Concomitant with Diffuse Large B-Cell Lymphoma: Case Report and Literature Review. Case Reports in Oncology. 2026;19(1):1451-1458. doi:10.1159/cro/abzag037
BibTeX
@article{Yasuda2026,
author = {Yasuda, Hajime and Ishii, Midori and Maruyama, Kyohei and Sano, Yuki and Kojima, Yuko and Abe, Yoshiyuki and Kinoshita, Shintaro and Hamano, Yasuharu and Ando, Jun and Ando, Miki},
title = {Anti-Transcriptional Intermediary Factor 1 Gamma Antibody-Positive Dermatomyositis Concomitant with Diffuse Large B-Cell Lymphoma: Case Report and Literature Review},
journal = {Case Reports in Oncology},
year = {2026},
volume = {19},
number = {1},
pages = {1451--1458},
doi = {10.1159/cro/abzag037}
}
EUVIMED